EU OKs $23B Novartis, GlaxoSmithKline 3-Part Deal
European regulators on Wednesday signed off on a series of deals between Novartis AG and GlaxoSmithKline PLC worth a combined $23 billion on the condition that the companies divest a number...To view the full article, register now.
Already a subscriber? Click here to view full article